---
title: "Hotgen: The business related to innovative biopharmaceuticals and early cancer screening is operated independently by a joint venture"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/247307174.md"
description: "According to the announcement of Hotgen regarding stock price fluctuations, the company's current main business is the research and development, production, and sales of in vitro diagnostic reagents and supporting instruments, as well as biopharmaceuticals and related businesses such as early cancer screening, which are independently operated by the company's joint ventures ShunJing Pharmaceutical, YaoJing Gene, ZhiYuan Bio, and AoRui Bio. These related businesses are characterized by high research and development investment and high research and development risks"
datetime: "2025-07-04T11:51:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/247307174.md)
  - [en](https://longbridge.com/en/news/247307174.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/247307174.md)
generator: "portal-rs"
---

# Hotgen: The business related to innovative biopharmaceuticals and early cancer screening is operated independently by a joint venture

According to the announcement from Zhitong Finance APP, Hotgen (688068.SH) has released a notice regarding stock price fluctuations, stating that the company's current main business is the research and development, production, and sales of in vitro diagnostic reagents and supporting instruments, as well as biopharmaceuticals and related businesses such as early cancer screening, which are independently operated by the company's joint ventures ShunJing Pharmaceutical, YaoJing Gene, ZhiYuan Bio, and AoRui Bio. These related businesses are characterized by high research and development investment and high research and development risks

### Related Stocks

- [688068.CN](https://longbridge.com/en/quote/688068.CN.md)

## Related News & Research

- [How Hong Kong infrastructure, AI firms are tapping Malaysia’s growth prospects](https://longbridge.com/en/news/296165689.md)
- [11:00 ETUnderstanding Lymph System Support Supplements: PureHealth Research Highlights Natural Ingredients for Everyday Wellness](https://longbridge.com/en/news/296684348.md)
- [China NMPA clears InnoCare Phase III trial of mesutoclax-azacitidine in treatment-naive AML](https://longbridge.com/en/news/296164458.md)
- [MORNING BID AMERICAS-Bonds out, robots in](https://longbridge.com/en/news/296340709.md)
- [CHAR Tech receives US patent notice of allowance for pyrogas treatment technology](https://longbridge.com/en/news/296486938.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**